SCHEMBL2708451

SCHEMBL2708451

COC(=O)c1ccc(F)cc1C(=O)OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.51
SLC6A3 Q01959 1/20 0.51
CA12 O43570 2/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA7 P43166 2/20 0.50
CA9 Q16790 2/20 0.50
CA14 Q9ULX7 2/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
PDK2 Q15119 2/20 0.50
CASP3 P42574 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
PDK4 Q16654 1/20 0.50
FFAR4 Q5NUL3 1/20 0.48
KDM4E B2RXH2 3/20 0.47
GAA P10253 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30301996 1.00 SLC6A4 (0.51) SLC6A4SLC6A3CA12CA1CA2
SCHEMBL16954819 0.90 SLC6A4 (0.47) SLC6A4SLC6A3CA12CA1CA2
SCHEMBL23729962 0.90 KEAP1 (0.52) SLC6A4SLC6A3CA12CA1CA2
SCHEMBL1957013 0.89 SLC6A4 (0.46) SLC6A4SLC6A3CA12CA1CA2
SCHEMBL1957011 0.89 SLC6A4 (0.46) SLC6A4SLC6A3CA12CA1CA2
SCHEMBL15273593 0.87 SLC6A4 (0.45) SLC6A4SLC6A3CA12CA1CA2
SCHEMBL112046 0.86 CES2 (0.61) SLC6A4SLC6A3CA12CA1CA2
SCHEMBL14012584 0.86 CES2 (0.61) SLC6A4SLC6A3CA12CA1CA2
SCHEMBL523258 0.86 CES2 (0.61) SLC6A4SLC6A3CA12CA1CA2
SCHEMBL27301248 0.84 SLC6A4 (0.43) SLC6A4SLC6A3CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129088-A1 CEREBLON E3 UBIQUITIN LIGASE INHIBITOR GAN & LEE PHARMACEUTICALS CO., LTD. (CN) 2025-04-24 US disclosed
EP-4471033-A1 CEREBLON E3 UBIQUITIN LIGASE INHIBITOR Gan & Lee Pharmaceuticals Co., Ltd. (CN) 2024-12-04 EP disclosed
CN-118632848-A Cerebellar protein E3 ubiquitin ligase inhibitors 甘李药业股份有限公司 2024-09-10 CN disclosed
CN-118201929-A PROTAC compound, pharmaceutical composition containing same, and preparation method and application thereof 广东弘烨医药科技有限公司 2024-06-14 CN disclosed
CN-118027041-A BTK inhibitor ring derivative and preparation method and pharmaceutical application thereof 西藏海思科制药有限公司 2024-05-14 CN disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
CN-117377675-A Bruton's tyrosine kinase degradation agent containing parallel ring or spiro ring 正大天晴药业集团股份有限公司 2024-01-09 CN disclosed
CN-113544130-B BTK inhibitor ring derivative and preparation method and pharmaceutical application thereof 西藏海思科制药有限公司 2024-01-09 CN disclosed
EP-3689868-B1 TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ARVINAS OPERATIONS INC (US) 2023-09-27 EP disclosed
EP-1813637-A1 RESIN COMPOSITION, POLYIMIDE RESIN COMPOSITION, POLY- BENZOXAZOLE RESIN COMPOSITION, VARNISHES, RESIN FILMS AND SEMICONDUCTOR DEVICES MADE BY USING THE SAME Sumitomo Bakelite Company, Limited (JP) 2007-08-01 EP disclosed
US-6699870-B2 Phthalazine compounds and therapeutic agents for erectile dysfunction EISAI CO., LTD. (JP) 2004-03-02 US disclosed
US-20030105074-A1 Phthalazine compounds and therapeutic agents for erectile dysfunction EISAI CO., LTD. 2003-06-05 US disclosed
US-6498159-B1 SUCH AS 4-((3-CHLORO-4-METHOXYBENZYL)AMINO)-1-((4-HYDROXY-4 -HYDROXYMETHYL)PIPERIDINO)-6-PHTHALAZINE CARBONITRILE EISAI CO., LTD. (JP) 2002-12-24 US disclosed
EP-1057819-A1 PHTHALAZINE DERIVATIVES AND REMEDIES FOR ERECTILE DYSFUNCTION Eisai Co., Ltd. (JP) 2000-12-06 EP disclosed
US-5322954-A Synthesis of 4-substituted phthalic anhydrides OCCIDENTAL CHEMICAL CORPORATION (US) 1994-06-21 US disclosed
EP-0238753-B1 N-SUBSTITUTED CONDENSED POLYMETHYLENE IMINE DERIVATIVES BEECHAM GROUP PLC (GB) 1992-01-15 EP disclosed
US-4959374-A HYPOTENSIVE AGENTS, ANTICOAGULANTS, GLAUCOMA, HYPERGLYCEMIC AGENTS, ANTIDEPRESSANTS BEECHAM GROUP P.L.C. (GB) 1990-09-25 US disclosed
US-4863946-A HYPOGLYCEMIC AND HYPOTENSIVE AGENTS BEECHAM GROUP PLC (GB) 1989-09-05 US disclosed
EP-0238753-A1 N-substituted condensed polymethylene imine derivatives BEECHAM GROUP PLC (GB) 1987-09-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129088-A1 CEREBLON E3 UBIQUITIN LIGASE INHIBITOR CRBN, UBE3A, UBE3C SLC6A4 4222/4885SLC6A3 2364/4885CA12 1839/4885
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN SLC6A4 3755/4885SLC6A3 3270/4885CA12 3256/4885
US-20030105074-A1 Phthalazine compounds and therapeutic agents for erectile dysfunction CLIC1, CBR1, CBR3 SLC6A4 1432/4885SLC6A3 634/4885CA12 1964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.